These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2797645)

  • 1. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model.
    Berek JS; Schink JC; Knox RM
    Obstet Gynecol; 1989 Oct; 74(4):663-6. PubMed ID: 2797645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro.
    Howell SB; Gill S
    Cancer Treat Rep; 1986 Mar; 70(3):409-10. PubMed ID: 3955553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.
    Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher SG; Fisher RI
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):102-9. PubMed ID: 1641650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination chemotherapy of paclitaxel followed by nedaplatin for human ovarian cancer].
    Uchida N; Yamada H; Maekawa R; Yoshioka T
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1943-9. PubMed ID: 12465394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent effectiveness of ADM and multiple cycles of DDP on a murine reticulum sarcoma.
    Leonetti C; Zupi G; Calabresi F; Greco C
    Anticancer Res; 1990; 10(1):45-8. PubMed ID: 2185688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.
    Etter AL; Bassi I; Germain S; Delaloye JF; Tschopp J; Sordat B; Dupuis M
    Gynecol Oncol; 2007 Oct; 107(1):14-21. PubMed ID: 17604087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
    Vanhaelen CP; Fisher RI
    Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.